Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: a phase I trial (GASTO-1021)

Esophageal cancer is the 9th most common malignancy and the mortality rank 6th globally [1]. In the East Asia, esophageal squamous cell carcinoma (ESCC) is the most frequently reported histologic type [2]. The majority of patients were initially diagnosed with advanced disease and lost the opportunity of curative surgery [3]. On the basis of Radiation Therapy Oncology Group (RTOG) 85-01, the standard therapeutic strategy for inoperable locally advanced disease is concurrent chemoradiotherapy (CCRT).

Source: Radiotherapy and Oncology - October 31, 2020 Category: Radiology Authors: Nai-Bin Chen, Qi-Wen Li, Su Li, Su-Ping Guo, Yin-Jia Wu, Zhang-Kai Cheng, Ji-Bin Li, Da-Quan Wang, Fang-Jie Liu, Xin-Lei Ai, Nan Hu, Bo Qiu, Hui Liu Tags: Original Article Source Type: research